Series A - T-Therapeutics
Investment Firm
Overview
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Announced Date
Nov 15, 2023
Funding Type
Series A
Highlights
Location
Europe
Social
Investor Lead
Digitalis Ventures
Digitalis Ventures is a early_stage_venture and late_stage_venture and seed and venture firm.
F-Prime Capital
F-Prime Capital is a early_stage_venture and late_stage_venture and seed and venture firm.
Sofinnova Partners
Sofinnova Partners is a early_stage_venture and late_stage_venture and seed firm.
Cambridge Innovation Capital
Cambridge Innovation Capital is a early_stage_venture and late_stage_venture and seed and venture firm.
Participant Investors
6
Round Details and Background
T-Therapeutics raised $59626218 on 2023-11-15 in Series A
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Company Funding History
1
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Nov 15, 2023 |  Series A - T-Therapeutics | 6 | - | 59.6M |
Recent Activity
There is no recent news or activity for this profile.